Neurobehavioral Disorders

FDA Approves First Generic Versions of Vyvanse

Brian Park, PharmD
|
Publish Date
Lisdexamfetamine dimesylate capsules and chewable tablets are indicated for ADHD in patients aged 6 years and older, and for moderate to severe binge-eating disorder in adults.

The Food and Drug Administration has approved the first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets.

Lisdexamfetamine dimesylate capsules and chewable tablets are indicated for attention-deficit/hyperactivity disorder (ADHD) in patients 6 years of age and older, and for moderate to severe binge-eating disorder (BED) in adults.

The approvals were granted to various manufacturers. Like the brand, the prescribing information for lisdexamfetamine dimesylate capsules and chewable tablets contains a Boxed Warning informing health care providers and patients about the potential risk for abuse and dependence. 

This article originally appeared on MPR

References:

US Food and Drug Administration. FDA approves multiple generics of ADHD and BED treatment. News release. Accessed August 28, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment?utm_medium=email&utm_source=govdelivery.